An Open Innovation Decision Support System to Select a Biopharmaceutical R&D Portfolio

Managerial and Decision Economics

Volumn 37, Issue 6, 2016, Pages 392-406

  Lo Nigro, Giovanna ^a   Morreale, Azzurra ^a   Abbate, Lorenzo ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926444366     PISSN: 01436570     EISSN: 10991468     Source Type: Journal    
DOI: 10.1002/mde.2727     Document Type: Article

References (65)

1. Arasteh A, Aliahmadi A, Omran MM. 2014. Application of gray systems and fuzzy sets in combination with real options theory in project portfolio management. Arabian Journal for Science and Engineering 39(8): 6489–6506.
2. Bardhan I, Bagchi S, Sougstad R. 2004. Prioritization of a portfolio of information technology projects. Journal of Management Information Systems 21(2): 33–60.
3. Betz U. 2011. Portfolio management in early stage drug discovery—a traveler's guide through uncharted territory. Drug Discovery Today 16: 609–618.
4. Bianchi M, Cavaliere A, Chiaroni D, Frattini F, Chiesa V. 2011. Organisational modes for open innovation in the bio-pharmaceutical industry: an exploratory analysis. Technovation 31(1): 22–33.
5. Black F, Scholes M. 1973. The pricing of options and corporate liabilities. Journal of Political Economy 81(3): 637–654.
6. Blau GE, Pekny JF, Varma VA, Bunch PR. 2004. Managing a portfolio of interdependent new product candidates in the pharmaceutical industry. The Journal of Product Innovation Management 21: 227–245.
7. Brach MA, Paxson DA. 2001. A gene to drug venture: Poisson options analysis. R&D Management 31: 203–214.
8. Brosch R. 2008. Portfolios of Real Options, Springer.
9. Carlsson C, Fullér R, Heikkilä M, Majlender P. 2007. A fuzzy approach to R&D project portfolio selection. International Journal of Approximate Reasoning 44: 93–105.
10. Cassimon D, Engelen PJ, Thomassen L, Van Wouwe M. 2004. The valuation of a NDA using a 6-fold compound option. Research Policy 33(1): 41–51.
11. Chesbrough H, Crowther AK. 2006. Beyond high tech: early adopters of open innovation in other industries. R&D Management 36(3): 229–236.
12. Chiaroni D, Chiesa V, Frattini F. 2008. Patterns of collaboration along the bio-pharmaceutical innovation process. Journal of Business Chemistry 5(1): 7–22.
13. Chien CF. 2002. A portfolio-evaluation framework for selecting R&D projects. R&D Management 32(4): 359–368.
14. Choi J, Realff MJ, Lee JH. 2004. Dynamic programming in a heuristically confined state space: a stochastic resource-constrained project scheduling application. Computers and Chemical Engineering 28: 1039–1058.
15. Chu YV, Hsu YL, Fehiling M. 1996. A decision support system for project portfolio selection. Computers in Industry 32(2): 141–149.
16. Collan M, Kyläheiko K. 2013. Forward-looking valuation of strategic patent portfolios under structural uncertainty. Journal of Intellectual Property Rights 18: 230–241.
17. Collan M, Luukka P. 2013. Evaluating R&D projects as investments by using an overall ranking from four new fuzzy similarity measure based TOPSIS variants. IEEE Transactions on Fuzzy Systems 21: 1–11.
18. Cooke P. 2005. Regionally asymmetric knowledge capabilities and open innovation exploring ‘globalisation 2’: a new model of industry organization. Research Policy 34: 1128–1149.
19. Cooper RG, Edgett SJ, Kleinshmidt EJ. 1998. Portfolio management for new products. Reading, MA: Perseus.
20. Copeland T, Antikarov V. 2001. Real Options: A Practitioner's Guide, Texere: New York.
21. Cox JC, Ross SA, Rubenstein M. 1979. Option pricing: a simplified approach. Journal of Financial Economics 7(3): 229–264.
22. Dickinson MW, Thornton AC, Graves S. 2001. Technology portfolio management: optimizing interdependent projects over multiple time periods. IEEE Transactions on Engineering Management 48(4): 518–527.
23. DiMasi JA, Grabowski HG. 2007. The cost of biopharmaceutical R&D: is biotech different? Managerial and Decision Economics 28(4–5): 469–479.
24. Dixit AK, Pindyck RS. 1994. Investment under Uncertainty, Princeton University Press: Princeton, NJ.
25. EFPIA. 2014. The Pharmaceutical industry in figures. Available at http://www.efpia.eu/uploads/Modules/Mediaroom/figs. 2014-final.pdf [accessed on 10 September 2014].
26. Fuss S, Szolgayova J, Khabarov N, Obersteiner M. 2012. Renewables and climate change mitigation: irreversible energy investment under uncertainty and portfolio effects. Energy Policy 40: 59–68.
27. Gassmann O, Enkel E, Chesbrough H. 2010. The future of open innovation. R&D Management 40(3): 213–221.
28. Ghasemzadeh F, Archer NP. 2000. Project portfolio selection through decision support. Decision Support Systems 29(1): 73–88.
29. Geske R. 1979. The valuation of compound options. Journal of Financial Economics 7(1): 63–81.
30. Giachetti R. (2012, May 16–17). Acquiring enterprise systems as a portfolio of real options. In Proceedings of the Ninth Annual Acquisition Research Symposium. Monterey, CA: Naval Postgraduate School.
31. Gustafsson J, Salo A. 2005. Contingent portfolio programming for the management of risk projects. Operations Research 53(6): 946–956.
32. Hassanzadeh F, Collan M, Modarres M. 2011. A technical note on a fuzzy set approach for R&D portfolio selection using a real options valuation model by Wang and Hwang (2007). Omega 39(4): 464–465.
33. Hassanzadeh F, Collan M, Modarres M. 2012. A practical approach to R&D portfolio selection using the fuzzy pay-off method. IEEE Transactions on Fuzzy Systems 20(4): 615–622.
34. Haug EG. 2007. The complete guide to option pricing formulas. McGraw-Hill. ISBN 0-07-138997-0
35. Henriksen AD, Traynor AJ. 1999. A practical R&D project-selection scoring tool. IEEE Transactions On Engineering. Management. 46(2):158–170.
36. Horowitz I. 1990. Decision making and estimation induced uncertainty. Managerial and Decision Economics 11(5): 349–358.
37. Huizingh E. 2011. Open innovation: state of the art and future perspectives. Technovation 31(1): 2–9.
38. Iamratanakul S, Patanakul P, Milosevic D. 2008. Project portfolio selection: from past to present, proceedings of the 4th IEEE international conference on management of innovation and technology, ICMIT, art. no. 4654378, 287–292.
39. Karsak EE 2006. A generalized fuzzy optimization framework for R&D project selection using real options valuation, In Computational Science and Its Applications - ICCSA 2006, Gavrilova MEA (Ed). ed Springer-Verlag:Berlin Heidelberg 918–927.
40. Lo Nigro G, Morreale A, Robba S, Roma P. 2013a. Biopharmaceutical alliances and competition: a real options games approach. International Journal of Innovation Management 17(6): 1340023. DOI: 10.1142/S1363919613400239.
41. Lo Nigro G, Enea G, Morreale A. 2013b. A user friendly real options based model to optimize pharmaceutical R&D portfolio. Journal of Applied Operational Research 5(3): 83–95.
42. Lo Nigro G, Morreale A, Enea G. 2014. Open innovation: a real option to restore value to the biopharmaceutical R&D. International Journal of Production Economics 149: 183–193.
43. Lo Nigro G, Perrone G, Chiapparrone S. 2012. Governance forms drivers in bio-pharmaceutical inter-firm relationships. International Journal of Production Economics 140: 604–613.
44. Loch CH, Bode-Greuel K. 2001. Evaluating growth options as sources of value for pharmaceutical research projects. R&D Management 31(2): 231–248.
45. Luehrman TA. 1998. Strategy as a portfolio of real options. Harvard Business Review September-October 76(5): 89–99.
46. Markowitz HM. 1952. Portfolio selection. Journal of Finance 7(1): 77–91.
47. Neely III JE, deNeufville R. 2001. Hybrid real options evaluation of risky product development projects. International Journal of Technology, Policy and Management 1: 29–46.
48. Novak DC, Ragsdale CT. 2003. A decision support methodology for stochastic multi-criteria linear programming using spreadsheets. Decision Support Systems 36(1): 99–116.
49. Pennings E, Lint O. 1997. The option value of advanced R&D. European Journal of Operational Research 103(1): 83–94.
50. Pennings E, Sereno L. 2011. Evaluating pharmaceutical R&D under technical and economic uncertainty. European Journal of Operational Research 212(2): 374–385.
51. Perlitz M, Peske T, Schrank R. 1999. Real options valuation: the new frontier in R&D project evaluation?. R&D Management 29(3): 255–270.
52. Phrma. 2013. 2013 Biopharmaceutical Research Industry Profile. Washington, DC: Phrma, Available at http://www.phrma.org/sites/default/files/pdf/PhRMA%20Profile%202013.pdf [accessed on 25 October 2013].
53. Pindyck RS, Rubinfeld DL. 2008. Microeconomics, 7th edn.: Pearson Prentice Hall.
54. Power DJ, Sharda R. 2007. Model-driven decision support systems: concepts and research directions. Decision Support Systems 43(3): 1044–1061.
55. Rafiee M, Kianfar F. 2011. A scenario tree approach to multi-period project selection problem using real-option valuation method. The International Journal of Advanced Manufacturing Technology 56: 411–420.
56. Rajapakse A, Titchener-Hooker NJ, Farid SS. 2006. Integrated approach to improving the value potential of biopharmaceutical R&D portfolios while mitigating risk. Journal of Chemical Technology and Biotechnology 81(10): 1705–1714.
57. Rogers MJ, Gupta A, Maranas CD. 2002. Real options based analysis of optimal pharmaceutical research and development portfolios. Industrial and Engineering Chemistry Research 41(25): 6607–6620.
58. Rogers MJ, Maranas CD, Ding M. 2005. Valuation and design of pharmaceutical R&D licensing deals. AICHE Journal 51(1): 198–209.
59. Rotheli TF. 1998. Forecasting among alternative strategies in the management of uncertainty. Managerial and Decision Economics 19(3): 179–187.
60. Smith JL, Thompson R. 2004. Managing a portfolio of real options: sequential exploration of dependent prospects MIT center for energy and environmental policy research, working paper no. 04-003WP, January, 2004.
61. Stirling C, Tuckey L. 2013. Price plan, innovation in pharmaceutical technology, KPMG Issue 4 Available at http://www.iptonline.com/pdf_viewarticle.asp?cat=1&article=940 (accessed on 10 September 2014)
62. van Bekkum S, Pennings E, Smit H. 2009. A real options perspective on R&D portfolio diversification. Research Policy 38(7): 1150–1158.
63. Zapata JC, Reklaitis GV. 2011. Valuation of project portfolios: an endogenously discounted method. European Journal of Operational Research 206(1): 653–666.
64. Wang J, Hwang WL. 2007. A fuzzy set approach for R&D portfolio selection using a real options valuation model. Omega 35(3): 247–257.
65. Wang CH, Min KJ. 2006. Electric power generation planning for interrelated projects: a real options approach. IEEE Transactions on Engineering Management 53(2): 312–322.